Burkitt's lymphoma medical therapy

Jump to navigation Jump to search

Burkitt's lymphoma Microchapters


Patient Information


Historical Perspective




Differentiating Burkitt's lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study Of Choice


History and Symptoms

Physical Examination

Laboratory Findings

X Ray Findings




Other Imaging Studies

Other Diagnostic Studies


Medical Therapy


Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Burkitt's lymphoma medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Burkitt's lymphoma medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Burkitt's lymphoma medical therapy

CDC on Burkitt's lymphoma medical therapy

Burkitt's lymphoma medical therapy in the news

Blogs on Burkitt's lymphoma medical therapy

Directions to Hospitals Treating Burkitt's lymphoma

Risk calculators and risk factors for Burkitt's lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2], Kamal Akbar, M.D.[3]


The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.

Medical Therapy

The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.[1]


CNS prophylaxis

Biological therapy

Stem cell transplant

  • A stem cell transplant may be offered to patients with recurrent Burkitt's lymphoma or to patients who relapse after the treatment.[2]


  1. Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015
  2. 2.0 2.1 2.2 Jacobson, C.; LaCasce, A. (2014). "How I treat Burkitt lymphoma in adults". Blood. 124 (19): 2913–2920. doi:10.1182/blood-2014-06-538504. ISSN 0006-4971.
  3. Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K; et al. (2018). "Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab". Br J Haematol. 181 (6): 782–790. doi:10.1111/bjh.15262. PMID 29741758.
  4. 4.0 4.1 Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E; et al. (2015). "AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma". Blood. 126 (2): 160–6. doi:10.1182/blood-2015-01-623900. PMC 4497960. PMID 25957391.
  5. Bortz, H.; Coutsouvelis, J.; Corallo, C. E.; Spencer, A.; Patil, S. (2015). "Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease". Journal of Clinical Pharmacy and Therapeutics. 40 (4): 483–485. doi:10.1111/jcpt.12293. ISSN 0269-4727.
  6. 6.0 6.1 Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W; et al. (2010). "Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia". J Clin Oncol. 28 (24): 3880–9. doi:10.1200/JCO.2009.26.9456. PMC 2940403. PMID 20660823.
  7. González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA; et al. (2016). "Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial". Ann Hematol. 95 (6): 893–9. doi:10.1007/s00277-016-2648-4. PMC 4853453. PMID 27025508.
  8. Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C; et al. (2017). "Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)". Haematologica. 102 (2): 235–245. doi:10.3324/haematol.2016.149120. PMC 5286932. PMID 27846613.
  9. Wiels J, Fellous M, Tursz T (1981). "Monoclonal antibody against a Burkitt lymphoma-associated antigen". Proc Natl Acad Sci U S A. 78 (10): 6485–8. PMC 349064. PMID 7031655.

Template:Chromosomal abnormalities

Template:WikiDoc Sources